# ALTTO (NCT00490139)

> ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00490139
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Neoplasms, Breast
- Interventions: Lapatinib; Trastuzumab
- Enrollment: 8381
- Primary outcome: Disease-Free Survival (DFS) at the Primary Analysis

## Commentary we found

- X threads: 30
- YouTube: 4
- Podcasts: 2
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=altto-nct00490139

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00490139", "email": "<work email>"}; the inbox owner confirms by the emailed link.